Aug 1, 2023 08:00AM
May 31, 2023 08:00AM
May 11, 2023 04:05PM
Apr 27, 2023 08:00AM
Apr 13, 2023 09:17AM
Mar 29, 2023 04:05PM
Feb 9, 2023 08:00AM IntelGenx Announces Research Collaboration with Renowned Neurologist to Evaluate Montelukast VersaFilm® for the Treatment of Parkinson’s Disease
Nov 22, 2022 07:30AM
Nov 10, 2022 04:05PM
Oct 25, 2022 08:00AM
Oct 18, 2022 08:00AM
Sep 8, 2022 08:00AM
Oct 12, 2021 08:00AM
Oct 21, 2020 07:00AM IntelGenx Enters Into Amended and Restated License Agreement with Tetra Bio-Pharma for Adversa® Mucoadhesive Delivery Technology for Dronabinol
Aug 13, 2020 04:02PM
Jun 11, 2020 08:00AM
May 27, 2020 08:00AM
May 14, 2020 04:02PM
Apr 6, 2020 08:00AM
Mar 27, 2020 11:46AM
Mar 26, 2020 07:00AM IntelGenx Reports Fourth Quarter and Full-Year 2019 Financial Results
Mar 23, 2020 08:00AM
Jan 15, 2020 08:00AM
Jan 13, 2020 08:00AM
Nov 7, 2019 04:01PM
Oct 22, 2019 08:00AM
Oct 9, 2019 08:00AM
Sep 26, 2019 04:34PM IntelGenx Announces Resubmission of RIZAPORT® New Drug Application
Aug 8, 2019 04:00PM
Jul 10, 2019 08:00AM
Jun 19, 2019 08:00AM
Jun 10, 2019 08:00AM
May 9, 2019 04:00PM
May 8, 2019 07:00AM
Apr 2, 2019 08:00AM IntelGenx Receives Complete Response Letter from FDA for RIZAPORT® NDA
Mar 22, 2019 04:05PM
Feb 14, 2019 08:00AM
Feb 7, 2019 04:00PM
Jan 30, 2019 08:00AM
Jan 23, 2019 08:00AM
Nov 20, 2018 08:02AM
Nov 20, 2018 08:00AM IntelGenx Announces FDA’s Acceptance of Resubmission of New Drug Application for RIZAPORT®
Nov 8, 2018 04:00PM
Oct 31, 2018 08:00AM
Oct 26, 2018 04:02PM
Oct 22, 2018 06:53PM
Oct 4, 2018 08:16AM
Sep 25, 2018 08:00AM
Sep 24, 2018 08:00AM IntelGenx Announces Successful Results from RIZAPORT® Bioequivalence Study
Jun 19, 2018 08:00AM

322,964 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All